SomaLogic And FDA Will Streamline Biosimilar Development

Agreement Aims To Identify Pharmacodynamic Biomarkers For Reference Biologics

 
• By Dean Rudge

Further to the US Food and Drug Administration’s own plans to develop a framework to further the use of pharmacodynamic biomarkers and potentially streamline biosimilar development, the FDA has joined forces with US-based specialist SomaLogic, gaining access to its proprietary technology platform.

Washington, D.C., USA- January 13, 2020: FDA Sign outside their headquarters in Washington DC. The Food and Drug Administration (FDA or USFDA) is a federal agency of the USA.
SomaLogic's proteomic strategy, if successful, could reduce the need for comparative clinical studies • Source: Shutterstock

More from Biosimilars

More from Products